hVISA/VISA: Diagnostic and therapeutic problems

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 1, 2009, Pages 1-3

  Szabó, Judit ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CEFTOBIPROLE; CEPHALOSPORIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; ORITAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN AGR; RAMOPLANIN; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; EDITORIAL; ERADICATION THERAPY; GENE FUNCTION; GENE MUTATION; HETEROGENEOUS VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; HUMAN; INFECTION CONTROL; LABORATORY DIAGNOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SENSITIVITY AND SPECIFICITY; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 67650761454     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.7.1.1     Document Type: Editorial

References (10)

1. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet 1, 147-155 (2001).
2. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth international supplement M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2008).
3. Hiramatsu K, Aritaka N, Hanaki S et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350, 1670-1673 (1997).
4. Liu C and Chambers FH. Staphylococcus aureus with heterogeous resistance to vancomycin: epidemiology, clinical significance and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47, 3040-3045 (2003).
5. Gould IM. Clinical relevance of increasing glycopeptides MICs against Staphylococcus aureus. Int. J. Antimicrob. Agents 31, 1-9 (2008).
6. Appelbaum PC. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30, 398-408 (2007).
7. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 42, S40-S50 (2006).
8. Gould IM. The problem with glycopeptides. Int. J. Antimicrob. Agents 30, 1-3 (2007).
9. Wootton M, Howe RA, Hillman R et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47, 399-404 (2001).
10. Yusof A, Engelhardt A, Karlsson A et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J. Clin. Microbiol. 46(9), 3042-3047 (2008).